首页>投融资
Veralox Therapeutics
未透露
Veralox Therapeutics Inc is a small molecule drug discovery and development company.In January 2021, VERALOX Therapeutics developing novel therapeutics that targets 12-Lipoxygenase.In June 2021, Veralox Therapeutics had closed a $16.6 million Series A financing.In September 2019, the company had raised $5.4 million round of financing.In January 2021, Veralox declared that the U.S. Food and Drug Administration granted Orphan Drug Designation for VLX-1005 for the treatment of HIT.In January 2021, Veralox announced that The FDA approved its Investigational New Drug Application for the initiation of Phase 1 clinical trial of VLX-1005 in HIT
基本信息
-
公司全称Veralox Therapeutics Inc
-
类型小分子药物发现和开发商
-
产业领域药品研发/制造、化学药
-
公司人数15人以下
-
地址4539 Metropolitan Ct FREDERICK MARYLAND 21704-9452; US; Telephone: +13013603502;
-
联系电话301-360-3502
-
邮箱
-
成立时间2017-09-01
投融资
-
2023-06-20未透露2400万美元JDRF T1D FundHatteras Venture PartnersNYBC VenturesPappas CapitalGenesys Capital赛诺菲
-
2021-06-16A轮1660万美元Alexandria Venture InvestmentsTEDCOJDRF T1D FundHatteras Venture PartnersVTC Innovation Fund赛诺菲Maryland Momentum FundGenesys Capital
-
2019-09-05种子轮540万美元TEDCO Gateway ServicesJDRF T1D FundVTC Innovation Fundthe University of Vermont Health Network赛诺菲Maryland Momentum FundVTC Seed Fund
相关投融资企业
A轮
Tasca Therapeuticstasca是一家私营生物技术公司，专注于发现和开发在癌症中很重要的自棕榈酰化靶蛋白的小分子抑制剂。该公司的主导项目CP-383是同类首创的候选药物，对多种癌症类型具有很好的临床前活性。
A轮
Ambrosia Biosciences Inc.是一家私营药物发现公司，开发口服小分子疗法治疗肥胖症和其他代谢紊乱。该公司的平台为体重管理和代谢健康提供非侵入性方法，与一些传统药物相比，使患者能够有效地管理自己的病情，副作用更少。
种子轮
RenaissThera is a pharmaceutical company focused on developing affordable and innovative therapies, particularly targeting high unmet medical needs in areas like cardio-metabolic disorders, oncology, and immunology. Additionally, Renaiss Thera utilizes generative AI to accelerate drug discovery and target identification.
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息